After breaking ground in October 2022 and fresh off its IPO in September 2023, SCHOTT Pharma opened the doors to an entirely new production facility for high-quality pre-fillable glass syringes in Hungary. Supported by a EUR 9 million (HUF 3.321 billion) investment from the local government, SCHOTT Pharma’s double-digit million Euro investment is realized with the opening of a facility that creates over 120 jobs.
- After EUR 76 million (HUF 28.044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens its newest production facility in Lukácsháza, Hungary
- Expanding production capacity will support pharma megatrends and market growth for prefillable syringes made of specialty glass
- With financial support from the local government, the facility brings over 120 new jobs to the area
With this move, SCHOTT Pharma is expanding its global capacities for strategically important high-value solutions that address key pharma trends. To supply the fast and dynamically growing market, SCHOTT Pharma plans to further invest a multi-million Euro amount in Hungary in pre-fillable syringes in the next years.
With an increasing number of drugs being stored in pre-fillable glass syringes – from GLP-1 drugs to critical vaccines and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the pharma industry,” said Andreas Reisse, CEO of SCHOTT Pharma.
As evidenced by their growing demand in the healthcare industry, these high-quality pre-fillable glass syringes not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians.
SCHOTT Pharma’s Hungarian site, that was inaugurated in Lukácsháza June 11, 2024, builds on the company’s existing foundation and pharmaceutical production skill-set in the area, which already plays an important role in supplying the global industry with drug containment systems today.
Following the high-end processes and advanced quality assurance found in SCHOTT Pharma’s global production network in 14 countries, the facility is equipped with state-of-the-art machinery. The new site is the second site where the company manufactures glass syringes, in addition to the site in St. Gallen in Switzerland.